Phase III SPARTAN study demonstrates survival benefit for apalutamide in combination with androgen deprivation therapy (ADT) compared to ADT alone in patients with non-metastatic castration-resistant prostate cancer

In study, median overall survival was significantly longer (73.9months for combination vs. 59.9 months for ADT alone; HR=0.78; p=0.0161). After study met its primary endpoint of metastasis-free survival, it was unblinded and patients on placebo allowed to crossover to apalutamide


Biospace Inc.